Article
Oncology
Benny Vittrup Jensen, Jakob Schou, Mette Yilmaz, Helle H. Johannesen, Kristin Skougaard, Dorte Linnemann, Estrid Hogdall, Finn O. Larsen, Julia S. Johansen, Per Pfeiffer, Dorte L. Nielsen
Summary: This study investigated the use of cetuximab and irinotecan in third-line treatment for mCRC patients, regardless of RAS or BRAF mutation status, and achieved certain efficacy. Shortening the treatment time while maintaining good treatment outcomes.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Review
Immunology
Xuan Wu, Wenping Song, Cheng Cheng, Ziyang Liu, Xiang Li, Yu Cui, Yao Gao, Ding Li
Summary: Three isoforms of RAS gene, KRAS, NRAS, and HRAS, are the most mutated family of small GTPases in cancer. While targeted immunotherapies have improved the survival of patients with non-KRAS-mutant cancer, RAS-mutant cancers still have a poor prognosis due to their high aggressiveness. However, recent advances in the use of allele-specific covalent inhibitors have led to the development of effective pharmacological interventions against RAS-mutant cancer, such as Sotorasib (AMG510) for KRAS-G12C mutant NSCLC. This review summarizes the progress and promise of small-molecule inhibitors in clinical trials to improve the prognosis of tumors with RAS mutations.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Alberto Sobrero, Heinz-Josef Lenz, Cathy Eng, Werner Scheithauer, Gary Middleton, Wenfeng Chen, Regina Esser, Johannes Nippgen, Howard Burris
Summary: The study investigated the efficacy of cetuximab plus irinotecan in RAS-wild-type metastatic colorectal cancer patients as second-line treatment, showing improvements in progression-free survival, objective response rate, and quality of life. Additionally, almost half of patients in the irinotecan arm received poststudy cetuximab therapy.
Article
Immunology
Antonio Hrvat, Mathias Schmidt, Martin Obholzer, Sonja Benders, Sebastian Kollenda, Peter A. Horn, Matthias Epple, Sven Brandau, Nina Mallmann-Gottschalk
Summary: The study explores the effects of different CaP-NPs on the anti-tumor activity of natural killer (NK) cells. Aggregated CaP-NPs can activate NK cell degranulation and impair antibody-dependent cellular cytotoxicity (ADCC). However, when properly dissolved, they do not cause substantial activation. Functionalized CaP-NPs coupled with therapeutic antibodies maintain high levels of ADCC activity.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Chwee Ming Lim, Anthony Liou, Michelle Poon, Liang Piu Koh, Lip Kun Tan, Kwok Seng Loh, Bengt Fredrik Petersson, Eric Ting, Dario Campana, Boon Cher Goh, Noriko Shimasaki
Summary: The study demonstrated that combining cetuximab with autologous expanded NK cells in patients with recurrent and/or metastatic NPC is safe and showed promising clinical responses, with some patients achieving durable stable disease.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Eric Van Cutsem, Rona Yaeger, Jean-Pierre Delord, Josep Tabernero, Lillian L. Siu, Michel Ducreux, Salvatore Siena, Elena Elez, Stefan Kasper, Thomas Zander, Neeltje Steeghs, Danielle Murphy, Michelle Edwards, Zev A. Wainberg
Summary: This study evaluated the combination of MEK1/2 inhibitor binimetinib and EGFR inhibitor panitumumab in patients with RAS-mutant or BRAF wild type/RAS wild-type metastatic colorectal cancer. The results showed limited clinical activity and substantial toxicity of the combination therapy in these patients.
Article
Oncology
Wentao Tang, Yu Liu, Meiling Ji, Tianyu Liu, Yijiao Chen, Aobo Zhuang, Yihao Mao, Wenju Chang, Ye Wei, Li Ren, Jianmin Xu
Summary: In this study, regardless of metastases resection or no resection, RAS and BRAF mutations were associated with a poor prognosis. Resection of metastases could bring survival benefits for patients regardless of RAS/BRAF status.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Sizhen Wang, Xiaohui Zhang, Xuemei Zou, Maorong Wen, Chi Gan, Xiaochun Jiang, Min Li, Rongxi Shen, Daojun Zhu, Anlong Yao, Yu Fang, Bernard A. Fox, Hong-Ming Hu, Guangjie Yu, Xinbo Wang
Summary: Adoptive cell therapy (ACT) using expanded tumor-infiltrating lymphocytes (TIL) or TCR gene-modified T cells (TCR-T) can induce tumor regression in patients with advanced pancreatic ductal adenocarcinoma (PDAC). However, the scarcity of TILs that recognize mutant KRAS and the poor immunogenicity of PDAC limit the widespread application of mutant KRAS-centric ACT. Researchers have attempted to increase the production of TILs by using K562-based artificial antigen-presenting cells (aAPC), but this leads to a loss of specificity to mutant KRAS. By using tandem mini gene-modified autologous T cells (TMG-T) as a novel aAPC, the generation of TIL cultures specifically reactive to mutant KRAS has been successfully achieved.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Review
Immunology
Erica L. Heipertz, Evan R. Zynda, Tor Espen Stav-Noraas, Andrew D. Hungler, Shayne E. Boucher, Navjot Kaur, Mohan C. Vemuri
Summary: Natural killer (NK) cells are a crucial part of the immune system, with the ability to kill virally infected and malignant cells. Current research is focused on testing the efficacy of NK cell therapy for cancer and exploring the use of CAR-NK for treatment.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Jonathan M. Loree, Yucai Wang, Muddassir A. Syed, Alexey Sorokin, Oluwadara Coker, Joanne Xiu, Benjamin A. Weinberg, Ari M. Vanderwalde, Anteneh Tesfaye, Victoria M. Raymond, Benjamin Miron, Gabi Tarcic, Ori Zelichov, Russell R. Broaddus, Patrick Kwok Shing Ng, Kang Jin Jeong, Yiu Huen Tsang, Gordon B. Mills, Michael J. Overman, Axel Grothey, John L. Marshall, Scott Kopetz
Summary: The study identified a high prevalence of atypical RAS mutations in colorectal cancer patients, which were associated with poor prognosis. Activating atypical variants were the most common in clinical cohorts, providing the best evidence to guide treatment.
CLINICAL CANCER RESEARCH
(2021)
Review
Cell Biology
Winston Hibler, Glenn Merlino, Yanlin Yu
Summary: Melanoma is a lethal form of cancer with limited treatment options. CAR-NK cell immunotherapies offer a promising alternative with better safety profile and fine-tuned cytotoxic activity.
Article
Oncology
G. Martini, D. Ciardiello, V. Famiglietti, D. Rossini, C. Antoniotti, T. Troiani, S. Napolitano, L. Esposito, T. P. Latiano, E. Maiello, M. Del Re, S. Lonardi, G. Aprile, D. Santini, G. Masi, A. Avallone, N. Normanno, F. Pietrantonio, C. Pinto, F. Ciardiello, C. Cremolini, E. Martinelli
Summary: The rechallenge strategy of cetuximab in third-line treatment of RAS/BRAF WT ctDNA mCRC patients shows promising results in terms of median PFS and OS. Skin rash is more frequently reported in CAVE trial, while increased incidence of hematological toxicities is observed in CRICKET trial. This therapy requires further investigation for its potential benefits and side effects.
Article
Oncology
Catherine G. Tran, Paolo Goffredo, Sarah L. Mott, Mohammed O. Suraju, Julia F. Kohn, Aditi Mishra, Jean-Nicolas Vauthey, Imran Hassan
Summary: This study investigates the impact of laterality, microsatellite instability (MSI), and KRAS status on conditional overall survival (COS) in colon cancer. The results show that mKRAS is associated with worse COS, suggesting a more aggressive biological behavior.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Shigenori Kadowaki, Toshiki Masuishi, Takashi Ura, Keiji Sugiyama, Seiichiro Mitani, Yukiya Narita, Hiroya Taniguchi, Kei Muro
Summary: The study evaluated the safety of FOLFOXIRI plus cetuximab in Japanese patients with RAS wild-type mCRC, and found that the combination therapy had acceptable safety profile and promising anti-tumor activity, supporting further research in this patient population.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Nutrition & Dietetics
Yu-Tang Chang, Chou-Chen Chen, Shih-Ching Chang, Yu-Yao Chang, Bo-Wen Lin, Hong-Hwa Chen, Yao-Yu Hsieh, Hung-Chih Hsu, Meng-Che Hsieh, Feng-Che Kuan, Chih-Chien Wu, Wei-Chen Lu, Yu-Li Su, Yi-Hsin Liang, Joe-Bin Chen, Shuan-Yuan Huang, Ching-Wen Huang, Jaw-Yuan Wang
Summary: This study investigated the efficacy and safety of a supplemental home parenteral nutrition (HPN) program for patients with RAS wild-type metastatic colorectal cancer (mCRC) receiving cetuximab plus chemotherapy. The HPN program group showed higher metastasectomy rate, longer duration of treatment and response, and improved progression-free survival (PFS) and overall survival (OS) compared to the non-HPN program group. These findings suggest that supplemental HPN programs may improve oncological outcomes in select patients with mCRC receiving targeted therapy plus chemotherapy.
Article
Oncology
Joeri A. J. Douma, Sonja Zweegman, Mieke Alberts, Sandy Kruyswijk, Niels C. W. J. van de Donk, Myra van Linde, Laurien M. Buffart, Henk M. W. Verheul
Summary: Objective smartphone measurements of physical activity and fitness are associated with early trial discontinuation, with high positive predictive values. Optimal cutoff values need to be externally validated in clinical practice.
SUPPORTIVE CARE IN CANCER
(2021)
Editorial Material
Immunology
James Di Santo, Nadja Bakocevic
EUROPEAN JOURNAL OF IMMUNOLOGY
(2021)
Review
Oncology
Tessa Hellingman, Merijn E. de Swart, Martijn W. Heymans, Elise P. Jansma, Hans J. van der liet, Geert Kazemier
Summary: The review and meta-analysis show that the disease-free interval is a prognostic factor for overall survival in patients undergoing repeat hepatectomy for recurrent CRLM, but it should not be the only criterion for selecting patients for repeat hepatectomy.
CANCER EPIDEMIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Marion Gransagne, Gabriel Ayme, Sebastien Brier, Gaelle Chauveau-Le Friec, Veronique Meriaux, Mireille Nowakowski, Francois Dejardin, Sylvain Levallois, Guilherme Dias de Melo, Flora Donati, Matthieu Prot, Sebastien Brule, Bertrand Raynal, Jacques Bellalou, Pedro Goncalves, Xavier Montagutelli, James P. Di Santo, Francoise Lazarini, Patrick England, Stephane Petres, Nicolas Escriou, Pierre Lafaye
Summary: This study developed a sandwich immunoassay to specifically detect the nucleoprotein (N) of SARS-CoV-2. Seven antibodies were identified that recognized the full N protein and did not cross react with nucleoproteins from common human coronaviruses. The antibodies mainly targeted conformational epitopes in the C-terminal or N-terminal domains and were able to detect SARS-CoV-2 variants.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2022)
Article
Immunology
Elza Evren, Emma Ringqvist, Jean-Marc Doisne, Anna Thaller, Natalie Sleiers, Richard A. Flavell, James P. Di Santo, Tim Willinger
Summary: Evren et al. identify CD116(+) fetal liver cells as precursors of human alveolar macrophages in early life and reveal the impact of cell origin on lung macrophage identity and function.
JOURNAL OF EXPERIMENTAL MEDICINE
(2022)
Article
Oncology
Jeanet F. Karchoud, Anja J. Th C. M. de Kruif, Femke Lamers, Myra E. van Linde, Joyce M. Van Dodewaard-de Jong, Annemarie M. J. Braamse, Mirjam A. G. Sprangers, Aartjan T. F. Beekman, Henk M. W. Verheul, Joost Dekker
Summary: This study explores the indicators and strategies used by oncologists and nurses to determine the need for professional mental health care in cancer patients. The findings suggest that oncologists and nurses consider multiple factors, including the patient's emotional well-being and specific indicators of emotional problems, when making the decision to refer patients for professional mental health care.
JOURNAL OF CANCER SURVIVORSHIP
(2023)
Article
Oncology
Mandy Gruijs, Rens Braster, Marije B. Overdijk, Tessa Hellingman, Sandra Verploegen, Rianne Korthouwer, Berend J. van der Wilk, Paul W. H. I. Parren, Hans J. van der Vliet, Marijn Boegels, Marjolein van Egmond
Summary: This study found that the use of low dose anti-EGFR mAbs prior to surgery in colorectal cancer patients can eliminate circulating tumor cells (CTCs) without interfering with wound healing, and may reduce the risk of liver metastasis, thus significantly improving long-term patient outcomes.
JOURNAL OF ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Tanmoy Saha, Amanda A. van Vliet, Chunxiao Cui, Jorge Jimenez Macias, Arpita Kulkarni, Luu Nhat Pham, Sean Lawler, Jan Spanholtz, Anna-Maria Georgoudaki, Adil Doganay Duru, Aaron Goldman
Summary: Allogeneic natural killer (aNK) cell adoptive therapy has the potential to impact clinical outcomes of glioblastoma multiforme (GBM). This study introduces a BBB-permissive supramolecular cationic drug vehicle containing a heat shock protein 90 (Hsp90) inhibitor that enhances GBM cell cytotoxicity and boosts the expression of MICA/B and ULBPs, thus improving the response to clinical-grade aNK cells.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Multidisciplinary Sciences
Nicolas Serafini, Angelique Jarade, Laura Surace, Pedro Goncalves, Odile Sismeiro, Hugo Varet, Rachel Legendre, Jean-Yves Coppee, Olivier Disson, Scott K. Durum, Gad Frankel, James P. Di Santo
Summary: Group 3 innate lymphoid cells (ILC3s) in the intestine remain activated for months after exposure to Citrobacter rodentium, leading to enhanced immune response and defense capability. These trained ILC3s undergo metabolic changes and exhibit enhanced proliferative capacity and IL-22 production.
Article
Surgery
J. K. de Bakker, L. L. Meijer, B. M. Zonderhuis, H. J. van der Vliet, F. Daams, N. C. T. van Grieken, B. Lissenberg-Witte, G. Kazemier
Summary: This study investigated the benefit of adjuvant chemotherapy for patients with resectable duodenal adenocarcinoma. The results showed no statistically significant survival benefit for adjuvant chemotherapy after curative resection in stages II and III patients. Future studies with specified treatment regimens and thorough stratification for prognostic factors are needed to determine the role of adjuvant therapy more definitively.
ACTA CHIRURGICA BELGICA
(2023)
Review
Hematology
Laura Surace, James P. Di Santo
Summary: This review discusses the role of innate lymphoid cells (ILCs) as metabolic sentinels and how specific activities of ILC subsets influence homeostasis and disease. Recent studies have found that ILCs' metabolism, phenotype, and function are shaped by signals from the tissue microenvironment. ILCs have emerged as crucial sensors of metabolic stress.
CURRENT OPINION IN HEMATOLOGY
(2022)
Article
Multidisciplinary Sciences
Carys A. Croft, Anna Thaller, Solenne Marie, Jean-Marc Doisne, Laura Surace, Rui Yang, Anne Puel, Jacinta Bustamante, Jean-Laurent Casanova, James P. Di Santo
Summary: The Notch signaling pathway plays a crucial role in the development of innate lymphoid cells (ILCs) from human ILC precursors. The study identifies a Notch->RORC->IL-23R pathway that regulates ILC differentiation. These findings may have implications for expanding functional ILC subsets in vitro and developing novel ILC therapies for human diseases.
NATURE COMMUNICATIONS
(2022)
Review
Immunology
Jose Saura-Esteller, Milon De Jong, Lisa A. King, Erik Ensing, Benjamin Winograd, Tanja D. De Gruijl, Paul W. H. I. Parren, Hans J. Van Der Vliet
Summary: Gamma delta T-cells can recognize and kill transformed cells independently of HLA-antigen presentation, making them a promising effector cell compartment for cancer immunotherapy. Current research is focused on the V delta 1 and V delta 2 T-cell subtypes, with V delta 1 enriched in tissues and V delta 2 enriched in circulation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Angelique Jarade, Zacarias Garcia, Solenne Marie, Abdi Demera, Immo Prinz, Philippe Bousso, James P. Di Santo, Nicolas Serafini
Summary: Serafini and colleagues find that intestinal villus ILC3s acquire migratory 'patrolling' attributes and enhanced cytokine expression in response to inflammation. These findings reveal notable differences between ILC3s and T cells in immunosurveillance, with ILC3s showing adaptation towards mucosal immunosurveillance after inflammation.
Review
Oncology
Nina Lamers-Kok, Denise Panella, Anna-Maria Georgoudaki, Haiping Liu, Didem Ozkazanc, Lucia Kucerova, Adil Doganay Duru, Jan Spanholtz, Monica Raimo
Summary: This review summarizes the clinical status of allogeneic NK cell-based therapies for hematological and solid tumors, discusses different cell sources, engineering methods, and combination therapies. It also reviews regulatory challenges and the competitive landscape, providing a comprehensive overview.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)